Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Matsui

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
International Journal of Clinical Pharmacology and Therapeutics|July 1, 1996
The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levelsF F Fassos, J Klein, D Fernandes, et al.
Neurology|August 26, 1998
Pregnancy outcome following first trimester exposure to sumatriptanS Shuhaiber, A Pastuszak, B Schick, et al.
Clinical Pharmacology and Therapeutics|January 1, 1994
Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemiaF F Fassos, J Klein, D Fernandes, et al.
Environmental Toxicology and Pharmacology|July 26, 2011
Pharmacokinetics of arginine butyrate in patients with hemoglobinopathyM Berkovitch, G Sher, R McCleland, et al.
European Journal of Clinical Pharmacology|March 17, 2007
British and Canadian views on the ethics of paediatric clinical trialsH M Sammons, J Malhotra, I Choonara, et al.
International Journal of Clinical Pharmacology, Therapy, and Toxicology|December 1, 1993
Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patientsS Stobie, J Tyberg, D Matsui, et al.
Clinical Pharmacology and Therapeutics|September 1, 1991
Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemiaD Matsui, J Klein, C Hermann, et al.
Blood|May 15, 1992
Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermediaN F Olivieri, G Koren, D Matsui, et al.
American Journal of Perinatology|January 16, 1999
A prospective controlled multicentre study of clarithromycin in pregnancyA Einarson, E Phillips, F Mawji, et al.
Bone Marrow Transplantation|January 1, 1993
Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patientsN F Olivieri, D Matsui, P P Liu, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
International Journal of Clinical Pharmacology and Therapeutics|July 1, 1996
The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levelsF F Fassos, J Klein, D Fernandes, et al.
Neurology|August 26, 1998
Pregnancy outcome following first trimester exposure to sumatriptanS Shuhaiber, A Pastuszak, B Schick, et al.
Clinical Pharmacology and Therapeutics|January 1, 1994
Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemiaF F Fassos, J Klein, D Fernandes, et al.
Environmental Toxicology and Pharmacology|July 26, 2011
Pharmacokinetics of arginine butyrate in patients with hemoglobinopathyM Berkovitch, G Sher, R McCleland, et al.
European Journal of Clinical Pharmacology|March 17, 2007
British and Canadian views on the ethics of paediatric clinical trialsH M Sammons, J Malhotra, I Choonara, et al.
International Journal of Clinical Pharmacology, Therapy, and Toxicology|December 1, 1993
Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patientsS Stobie, J Tyberg, D Matsui, et al.
Clinical Pharmacology and Therapeutics|September 1, 1991
Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemiaD Matsui, J Klein, C Hermann, et al.
Blood|May 15, 1992
Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermediaN F Olivieri, G Koren, D Matsui, et al.
American Journal of Perinatology|January 16, 1999
A prospective controlled multicentre study of clarithromycin in pregnancyA Einarson, E Phillips, F Mawji, et al.
Bone Marrow Transplantation|January 1, 1993
Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patientsN F Olivieri, D Matsui, P P Liu, et al.
Pageof 4